Pasritamig (JNJ-78278343, KLCB-245) is a Human kallikrein 2 (KLK2) and CD3 receptor complex binder. Pasritamig directs T-cell cytotoxicity to KLK2-expressing tumor cells, induces T-cell-mediated lysis of KLK2-expressing prostate cancer cells. Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig demonstrates a safety profile with very low rates of cytokine release syndrome, and can be safely administered in an outpatient setting. Pasritamig can be used for the research of metastatic castration-resistant prostate cancer[1].
Molekulargewicht:
(124.81 kDa)
Reinheit:
99.42
CAS Nummer:
[2921676-04-0]
Target-Kategorie:
CD3
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
